Latest / Ageless and Timeless Podcast® / Reversing Age with Science: Ryan Smith on Epigenetics, Peptides, and the Future of Longevity

Transcript

Reversing Age with Science: Ryan Smith on Epigenetics, Peptides, and the Future of Longevity · Ageless and Timeless Podcast®

• 0:09
  Speaker 1: Good morning everyone. This is Michelle Hughes from Ageless and Timeless.
• 0:13
  Speaker 1: Today I have Ryan Smith, the founder and now the
• 0:17
  Speaker 1: scientific director. I thought Ryan, when you were on last time,
• 0:21
  Speaker 1: there was a different title, but we're going with what
• 0:24
  Speaker 1: I see on the internet now as chief Scientific Director.
• 0:29
  Speaker 1: Is that correct?
• 0:30
  Speaker 2: Yeah? Absolutely. You know, I was working sort of as
• 0:33
  Speaker 2: a CEO prior, but now with all the science and
• 0:35
  Speaker 2: developments going on, I've sort of transitioned full time to
• 0:38
  Speaker 2: research and development and so excited to share that and
• 0:41
  Speaker 2: some of the updates we have today.
• 0:42
  Speaker 1: Yeah, and you were on I think two years at
• 0:45
  Speaker 1: twenty twenty three, I think is when we first had
• 0:48
  Speaker 1: you on. So there's so much that's happened. I mean, honestly,
• 0:52
  Speaker 1: you've taken warp speed. I've never seen a company do
• 0:56
  Speaker 1: as much in two years as True Diagnostics has done.
• 1:00
  Speaker 1: So we're going to hear all about that today. And
• 1:03
  Speaker 1: the other exciting news is that I did take my
• 1:06
  Speaker 1: second test with Ryan for the True Diagnostics and again
• 1:13
  Speaker 1: I just got the results this morning, and everybody, you
• 1:16
  Speaker 1: will be so blown away by how comprehensive this test is.
• 1:20
  Speaker 1: And it takes a while actually to just go through
• 1:24
  Speaker 1: it and to try to digest, and of course you
• 1:26
  Speaker 1: need some guidance from someone like Ryan, who are your
• 1:30
  Speaker 1: medical professional who you'd be taking it through to understand
• 1:35
  Speaker 1: all that the implications suggest to you. But there's so
• 1:39
  Speaker 1: much that you can derive from this that it will
• 1:42
  Speaker 1: really reduce the amount of time you have to spend
• 1:45
  Speaker 1: running around to a bunch of specialists if you just
• 1:48
  Speaker 1: take this test. So we're going to go through that today.
• 1:51
  Speaker 1: We're going to make this like a tutorial, very different
• 1:54
  Speaker 1: than my normal podcast. But why don't we start off
• 1:57
  Speaker 1: Ryan by just giving us a little background about your journey.
• 2:01
  Speaker 1: Ken Coletorf was on the other day and he, you know, which,
• 2:05
  Speaker 1: started chatting about Taylor Made. And Taylor Made was the
• 2:08
  Speaker 1: first company that Ryan actually founded right out of medical school.
• 2:12
  Speaker 1: So give us a little bit of a history of
• 2:14
  Speaker 1: how this all happens so people know who you are.
• 2:17
  Speaker 2: Yeah, certainly, it's it's been a crazy journey for myself,
• 2:20
  Speaker 2: but you know, as you mentioned, surely out of medical
• 2:24
  Speaker 2: school I started Tailor Made compounding, and my background previously
• 2:29
  Speaker 2: and even medical school, I'd been in peptide and protein synthesis,
• 2:33
  Speaker 2: so sort of making peptides from the ground up, and
• 2:36
  Speaker 2: so in really in two thousand and sixteen, which is
• 2:40
  Speaker 2: the first year, we had an idea to start tailor
• 2:42
  Speaker 2: made compounding, to really offer innovative peptides through compounding pharmacy.
• 2:47
  Speaker 2: So we brought a lot of the peptides you might
• 2:49
  Speaker 2: be familiar with to market, things like the BPC one
• 2:51
  Speaker 2: five seven. We own the patent for the pre milantide pte.
• 2:56
  Speaker 2: We brought to the market. You know, we brought even
• 2:59
  Speaker 2: you know timis and beta, thymus and alpha, if you
• 3:02
  Speaker 2: name it peptid. We were really one of the first
• 3:04
  Speaker 2: to commercialize it. And as most people know, the peptides
• 3:08
  Speaker 2: are really really popular. But we sort of built that market,
• 3:11
  Speaker 2: but we grew at a really rapid speed, and so
• 3:13
  Speaker 2: we were the fourth fastest growing company in healthcare. We
• 3:16
  Speaker 2: went from sort of me as the first employee to
• 3:18
  Speaker 2: two hundred and fifty within a little over two and
• 3:21
  Speaker 2: a half years. So it was sort of incredible growth,
• 3:24
  Speaker 2: mainly because these peptides were so exciting. But we also
• 3:27
  Speaker 2: knew that one of the limitations there would be the
• 3:30
  Speaker 2: FDA and some of the lack of data on a
• 3:32
  Speaker 2: lot of these products, and so in the back of
• 3:34
  Speaker 2: our of my mind, specifically I was always looking for
• 3:37
  Speaker 2: ways to try and see how these things were helping,
• 3:39
  Speaker 2: but we didn't have time for you know, twenty or
• 3:42
  Speaker 2: forty year pacebo control trials, and so one of the
• 3:46
  Speaker 2: tools to measure this that really caught my eye during
• 3:50
  Speaker 2: that Tailorman compounding experience was these epigenetic clocks. So these
• 3:54
  Speaker 2: clocks which are reading not your DNA, but your gene
• 3:57
  Speaker 2: expression patterns how your genes are turned on and off
• 3:59
  Speaker 2: to tell you about how you're aging. And so these
• 4:02
  Speaker 2: clocks have been going on a while, really since twenty
• 4:06
  Speaker 2: thirteen was their first appearance, but really in twenty eighteen,
• 4:10
  Speaker 2: for the first time, they had the first ever interventional
• 4:13
  Speaker 2: data where they were looking at things like met foreman
• 4:15
  Speaker 2: growth hormone and DHA to see if they could actually
• 4:18
  Speaker 2: reverse the aging process. And because aging is the biggest
• 4:21
  Speaker 2: respector for every chronic disease and death, it became a
• 4:26
  Speaker 2: clock that I was really really interested in. So unfortunately,
• 4:30
  Speaker 2: finally the FDA came knocking at our door and we
• 4:32
  Speaker 2: really had to stop doing a lot of the peptides.
• 4:34
  Speaker 2: But I used that as an opportunity to sort of
• 4:37
  Speaker 2: sell an exit the business to create true diagnostic which
• 4:39
  Speaker 2: really focused on DNA methylation, particularly the DNA methylation age
• 4:43
  Speaker 2: clocks to sort of quantify aging. And so that started
• 4:47
  Speaker 2: in twenty twenty and then here we are now five
• 4:50
  Speaker 2: years later, actually to the month actually, and a lot
• 4:54
  Speaker 2: has happened. DNA mefilation clocks have come a long way.
• 4:58
  Speaker 2: But the other things that we can do with the inflation,
• 5:01
  Speaker 2: and we'll talk about today, I think are equally is exciting.
• 5:04
  Speaker 1: Well, this is so good. And you know, I know,
• 5:06
  Speaker 1: out of adversity comes opportunity. And in your case, look
• 5:10
  Speaker 1: what happened. You know, yes, you left medical school because
• 5:13
  Speaker 1: you were disenchanted. That's an adversity at that time. And
• 5:17
  Speaker 1: look what happened with Taylor Made. Then Taylor Made looked
• 5:21
  Speaker 1: like an adversity as the outcome of that company. And
• 5:24
  Speaker 1: now look what happened with True Diagnostics. So you're you're
• 5:28
  Speaker 1: like a poster child for creating opportunity out of adversity.
• 5:32
  Speaker 1: And this is certainly something that we all as entrepreneurs,
• 5:36
  Speaker 1: you know, and people that are looking for answers to
• 5:40
  Speaker 1: health issues, we always look to people like you and
• 5:44
  Speaker 1: hopefully you know others many of the others that have
• 5:47
  Speaker 1: been on my podcasts who have had similar situations, including
• 5:51
  Speaker 1: myself that you know, we have something that occurs that
• 5:56
  Speaker 1: looks like it's a terrible event, and then somehow we
• 6:01
  Speaker 1: look back and we say, look what that event did
• 6:04
  Speaker 1: and how it turned my life around. So exactly who knows?
• 6:07
  Speaker 1: To you, Ryan, So let's just do a few definitions
• 6:11
  Speaker 1: for people who are tuning in for the first time,
• 6:14
  Speaker 1: didn't see your last podcast, and many who might not
• 6:18
  Speaker 1: understand these terms. So let's start with peptide. What is
• 6:21
  Speaker 1: a peptide?
• 6:23
  Speaker 2: Yeah, so a peptide is just a short chain of
• 6:26
  Speaker 2: amino acids. Usually the definition is under forty in length.
• 6:30
  Speaker 2: So if you're familiar with the amino acids, they make up
• 6:33
  Speaker 2: peptides and proteins of the body, sort of what we
• 6:35
  Speaker 2: call the infrastructure of the body. But peptides in particular
• 6:39
  Speaker 2: can be signaling molecules acting like hormones or you know,
• 6:43
  Speaker 2: drugs in and of themselves. But they're just short chains
• 6:46
  Speaker 2: of amino acids.
• 6:47
  Speaker 1: Right, And how do you differentiate between a peptide and
• 6:51
  Speaker 1: a peptide bioregulator which you and I how we met
• 6:56
  Speaker 1: actually was through doctor Bill Lawrence, who was a disciple
• 7:00
  Speaker 1: of doctor Cavinson from Saint Petersburg, Gerontology. Unfortunately he's passed
• 7:06
  Speaker 1: away last year or two years ago. Again are a
• 7:09
  Speaker 1: lot of last year, and but you know the work
• 7:11
  Speaker 1: he's done lives on, and so distinguish those two.
• 7:16
  Speaker 2: Yeah, well, so the bioregulators are still peptides. So for instance,
• 7:20
  Speaker 2: you think about things like the epitalon or the thimulin,
• 7:23
  Speaker 2: those are still short chain amino acids. You know, usually
• 7:26
  Speaker 2: the bioregulators are anywhere from eight. Amino acids are less,
• 7:30
  Speaker 2: and they're they're meant to come from natural sources uh
• 7:33
  Speaker 2: and and work on you know, individual products. But but
• 7:36
  Speaker 2: peptides generally can be you know, we have a lot
• 7:39
  Speaker 2: of amino acids uh and and you know we can
• 7:42
  Speaker 2: have multiple combinations as those peptide chains get larger and
• 7:46
  Speaker 2: uh and and so how those peptides are designed really
• 7:48
  Speaker 2: ultimately influence how they're going to peck the body. But
• 7:51
  Speaker 2: but both are are the same chain of amino acids,
• 7:53
  Speaker 2: just technically different, uh you know, subdivisions of that category.
• 7:57
  Speaker 1: And and the other justinction is that the pep type
• 8:01
  Speaker 1: bioregulators do attach themselves to specific organs, kind of like
• 8:06
  Speaker 1: the pluripotent stem cells. So like you could take a
• 8:11
  Speaker 1: pep type bioregulator specifically for your heart, or for your lungs,
• 8:17
  Speaker 1: or for your bone marrow or your thymus or whatever.
• 8:21
  Speaker 1: So that's a little different, don't you think than the
• 8:25
  Speaker 1: generalized general generic peptides.
• 8:28
  Speaker 2: Well, you know, one of the things about the bioregulators
• 8:31
  Speaker 2: is the you know, outside of a few like thymulan
• 8:34
  Speaker 2: or epitalent, they don't have a lot of published data
• 8:37
  Speaker 2: and so so you know, those are certainly claims. But
• 8:40
  Speaker 2: but but I don't know that I've seen anything that
• 8:42
  Speaker 2: would back that up. You know, generally the peptides are
• 8:46
  Speaker 2: hitting extracellular receptors and and and so generally they might
• 8:51
  Speaker 2: be optimized for certain organ or another, like for instance,
• 8:55
  Speaker 2: the epitalent or the penlon or for the peneal gland
• 8:59
  Speaker 2: or mimicking products that come from that organ, and so sore,
• 9:02
  Speaker 2: they're certainly I would say, different categories, but really every
• 9:07
  Speaker 2: peptide is unique and different.
• 9:09
  Speaker 1: Okay, all right, well, good, that's good to know. Okay,
• 9:11
  Speaker 1: Now let's talk about the difference between chronological aging and
• 9:15
  Speaker 1: biological aging. That's some like an ABC of understanding you're
• 9:20
  Speaker 1: what you're doing at true diagnostics exactly.
• 9:23
  Speaker 2: It's fundamental, you know, aging, no matter if we're talking
• 9:27
  Speaker 2: about chronological or biological. It's the biggest risk factor for
• 9:30
  Speaker 2: every disease. But the problem with chronological age is that
• 9:33
  Speaker 2: it's not really as informative as we want it to be.
• 9:36
  Speaker 2: You know, we all probably know people in their seventies
• 9:38
  Speaker 2: who look like they're fifty and vice versa, and so
• 9:41
  Speaker 2: it's not really informing us about the biology of how
• 9:45
  Speaker 2: healthy someone actually is. And so biological age is sort
• 9:48
  Speaker 2: of a calculation to tell us more about how someone
• 9:51
  Speaker 2: is aging on a molecular or physical process level, and
• 9:54
  Speaker 2: it's much much more informative. It's much more predictive of
• 9:57
  Speaker 2: outcomes than just your chronological age.
• 9:59
  Speaker 3: Today, this podcast is brought to you by g Genics.
• 10:03
  Speaker 3: From stem cell therapy to lifestyle coaching, Gigenics is the
• 10:07
  Speaker 3: perfect place to go for all your health and wellness needs.
• 10:12
  Speaker 3: This health clinic is amazing at getting you personalized medicine
• 10:16
  Speaker 3: and wellness that is unique to you. Use the code
• 10:19
  Speaker 3: ageless and you'll get twenty percent off your first service
• 10:23
  Speaker 3: with them. Go to www dot g Genics qi ge
• 10:29
  Speaker 3: nix dot com to find out more information about these
• 10:34
  Speaker 3: powerful methods. So the chronologically, just to simplify, is the
• 10:39
  Speaker 3: number of years you've been you've gone around the sun,
• 10:43
  Speaker 3: and it's just a number. This is why people say
• 10:46
  Speaker 3: aging is just a number or age is just a number.
• 10:48
  Speaker 1: I mean're not aging. That's not correct. Age is just
• 10:52
  Speaker 1: a number, But biological age is really aging is really
• 10:56
  Speaker 1: telling you how old are your organs or how old
• 10:59
  Speaker 1: are you systemically metabolically. So that's a huge difference, and
• 11:06
  Speaker 1: I think more and more people are starting to differentiate
• 11:09
  Speaker 1: in you know, their discussions about aging between the biological
• 11:14
  Speaker 1: and the chronological. So I agree with you that chronological
• 11:17
  Speaker 1: age can just be put aside when you're looking at
• 11:21
  Speaker 1: you know, how long are we going to live? It's
• 11:23
  Speaker 1: really your biological age is going to determine your lifespan,
• 11:27
  Speaker 1: So then talk about lifespan and health span.
• 11:31
  Speaker 2: Yeah, definitely. You know, obviously when people think about aging,
• 11:35
  Speaker 2: they think about both, right, how long they will live,
• 11:38
  Speaker 2: but they also think about some of the negative type
• 11:40
  Speaker 2: of events that happen with aging. Right. We we generally
• 11:43
  Speaker 2: might have our cognitive function decrease, or we might be
• 11:46
  Speaker 2: less mobile and have trouble moving as much. You know,
• 11:49
  Speaker 2: we might have you know, a difficulty even sustaining attention sometimes,
• 11:53
  Speaker 2: or we might have facial aging. All of these things
• 11:55
  Speaker 2: are biological driven processes and so so that's really what
• 12:00
  Speaker 2: we're trying to quantify is all of that. But the
• 12:02
  Speaker 2: good news is that health span and lifespan are both
• 12:05
  Speaker 2: pretty linked. You know, generally, the more that you're improving
• 12:08
  Speaker 2: your health span, the more you're improving your lifespan, and
• 12:10
  Speaker 2: vice versa. There are different they're giving us some different signals,
• 12:15
  Speaker 2: even moleculy when we're trying to predict both. They're slightly different,
• 12:19
  Speaker 2: but ultimately they're very, very correlated, and generally, if you're
• 12:22
  Speaker 2: improving one, you're improving the other.
• 12:24
  Speaker 1: And so what about epigenetics. How is you know, so
• 12:27
  Speaker 1: many people are taking DNA tests today and there's so
• 12:30
  Speaker 1: many companies offering although my favorite is the DNA Company,
• 12:34
  Speaker 1: And as you know, we've talked about Kushief Khan and
• 12:37
  Speaker 1: Tracy Wood and I've done their test twice now, just
• 12:41
  Speaker 1: like I've done your test twice. So I have really
• 12:43
  Speaker 1: good feelings about the depth of their testing. But the
• 12:47
  Speaker 1: key thing for people to understand about the DNA company
• 12:51
  Speaker 1: is it's an epigenetic test and it's not like twenty
• 12:55
  Speaker 1: three and meis, which is of course now defunct, but
• 12:59
  Speaker 1: were and and DNA company never sells your data. So
• 13:04
  Speaker 1: let's talk about the you know, the key differences of
• 13:07
  Speaker 1: all these different DNA tests that are out there. But
• 13:11
  Speaker 1: how do you differentiate from your perspective?
• 13:14
  Speaker 2: Yeah, definitely. So the the you know DNA, right is
• 13:18
  Speaker 2: it tests like you would do for twenty three, I
• 13:19
  Speaker 2: mean it never changes. You take that test once in
• 13:21
  Speaker 2: a lifetime exactly, And and but epigenetics is slightly different.
• 13:26
  Speaker 2: What we're basically measuring is how turned on and turned
• 13:29
  Speaker 2: off certain genes are. And and unfortunately, these these gene
• 13:34
  Speaker 2: sort of activity levels are highly correlated with health and disease.
• 13:38
  Speaker 2: You know, originally these clocks started by predicting just someone's
• 13:42
  Speaker 2: chronological age, but this data set on epigenetics can now
• 13:47
  Speaker 2: do a lot more than even just your chronological or
• 13:49
  Speaker 2: biological age. We can tell your risk of certain diseases.
• 13:53
  Speaker 2: We can tell you what you're eating in life, we
• 13:55
  Speaker 2: can tell you what ZIP code you've lived in based
• 13:57
  Speaker 2: on pollution markers in your DNA. So really, the way
• 14:00
  Speaker 2: that I like to describe epigenetics as sort of a
• 14:01
  Speaker 2: log of everything that's going on in your life. It's
• 14:05
  Speaker 2: sort of all of your behaviors, it's even close psychological relationships.
• 14:09
  Speaker 2: Your gene expression is constantly adapting to try and give
• 14:13
  Speaker 2: you the most optimal health, you know, so that if
• 14:15
  Speaker 2: you encounter some type of illness, you can adapt, or
• 14:18
  Speaker 2: if you have a metabologicysfunction, you can adapt. And so
• 14:22
  Speaker 2: there are over twenty nine million epigenetic regions that we
• 14:26
  Speaker 2: would measure in every cell. We call these sort of CPGs.
• 14:31
  Speaker 2: That's where these methylation groups are attached, and so we're
• 14:34
  Speaker 2: sort of measuring the off switch. And so really we
• 14:38
  Speaker 2: measure millions of different locations and every single site we
• 14:42
  Speaker 2: get a number of zero to one. The closer it
• 14:45
  Speaker 2: is to one, the more turned off that gene is.
• 14:47
  Speaker 2: And the closer it is to zero, the more turned
• 14:49
  Speaker 2: on that gene is. And that's not necessarily a good
• 14:53
  Speaker 2: or a bad thing, but we can read those patterns.
• 14:56
  Speaker 2: We sort of always try and joke and say that
• 14:58
  Speaker 2: we're creating the Rosetta stone of unders standing that data set.
• 15:01
  Speaker 2: So what we're trying to do is to use really
• 15:04
  Speaker 2: artificial intelligence with lots of data like that numbers between
• 15:07
  Speaker 2: zero and one, and then also outcome data so we
• 15:10
  Speaker 2: can try and predict the things that we're trying to predict.
• 15:12
  Speaker 2: So it's a biological age. We might try and predict
• 15:15
  Speaker 2: that to time until death, So how long do you
• 15:18
  Speaker 2: have to live to create a biolo o'clock. We might
• 15:21
  Speaker 2: though do it to do when do people start developing
• 15:24
  Speaker 2: Alzheimer's disease or do people have Alzheimer's disease? Or how
• 15:28
  Speaker 2: much weight might you lose if you take a gop one.
• 15:31
  Speaker 2: So this data set is a really really robust data
• 15:34
  Speaker 2: set that can do a lot of things. But we're
• 15:36
  Speaker 2: really just measuring your gene expression, how turned on or
• 15:39
  Speaker 2: turned off different genes are.
• 15:41
  Speaker 1: And in those the term epigenetic really does mean lifestyle.
• 15:45
  Speaker 1: So it means really that you're not given a death
• 15:49
  Speaker 1: sentence by your gene what comes out of your DNA test,
• 15:53
  Speaker 1: Because if your genes, like you're just saying, if your
• 15:55
  Speaker 1: genes are towards the turnoff side, but it's a negative
• 15:58
  Speaker 1: gene like the APO four or Alzheim gene, but you're
• 16:03
  Speaker 1: not you know, it's not actively being inspired, let's say,
• 16:09
  Speaker 1: in your body, because you're doing a lot of lifestyle
• 16:11
  Speaker 1: things to prevent that. So I think that's a key
• 16:14
  Speaker 1: thing for people not to look at their DNA results
• 16:17
  Speaker 1: as a life and death sentence and then you know,
• 16:20
  Speaker 1: give up because oh I'm going to get all times
• 16:23
  Speaker 1: because I have the APO for alile. That's not true.
• 16:27
  Speaker 1: You may never see an activation of that gene even
• 16:30
  Speaker 1: though your parents gave it to you.
• 16:33
  Speaker 2: Yeah, exactly, I'm an April week three four, so so
• 16:36
  Speaker 2: you know that's particularly relevant to me. But but yeah,
• 16:39
  Speaker 2: I think that you know, we've done what we call
• 16:41
  Speaker 2: heritability analysis for things like longevity, and we see that
• 16:45
  Speaker 2: the good majority, probably about seventy percent is still based
• 16:48
  Speaker 2: on behaviors versus you know, thirty percent that might be
• 16:51
  Speaker 2: inherited genetically, and so that's still the large majority, which
• 16:54
  Speaker 2: I hope makes everyone feel a little bit more empowered
• 16:58
  Speaker 2: to take care of their own health. But that is
• 17:00
  Speaker 2: the good point is that you know, with the DNA tests,
• 17:03
  Speaker 2: you generally your DNA won't change across a lifetime. However,
• 17:07
  Speaker 2: genetics it's changeable, and so it sort of allows us
• 17:11
  Speaker 2: to take a baseline see where we're at and then
• 17:13
  Speaker 2: ultimately help improve our health by by you know, giving
• 17:16
  Speaker 2: interventions and then trying to measure it again to see
• 17:18
  Speaker 2: which direction we're going.
• 17:20
  Speaker 1: Okay, so let's talk about telomeres. I noticed that the
• 17:23
  Speaker 1: telomeres that you did in the first test with me
• 17:27
  Speaker 1: in twenty twenty three, I didn't see in this test.
• 17:29
  Speaker 1: Is that a conscious decision that you made not to
• 17:32
  Speaker 1: include telomere length.
• 17:34
  Speaker 2: So we still have telomere length, but to be honest
• 17:36
  Speaker 2: with you, we don't love it. And the reason is
• 17:40
  Speaker 2: it's not very predictive of health outcomes. And so a
• 17:43
  Speaker 2: recent study was done by Ricardo Marioni out of University
• 17:48
  Speaker 2: of Edinburgh and they really telamere link effects right around
• 17:52
  Speaker 2: two point eight percent of the phenotypes of aging and
• 17:56
  Speaker 2: is really really tiny. Even the earliest epigenetic flox explain
• 18:00
  Speaker 2: over twenty eight percent variants in aging, and the newest
• 18:03
  Speaker 2: epigenetic clocks are more like sixty percent apigenetic aging process.
• 18:08
  Speaker 2: And so tilameres are a certain part of aging biology,
• 18:11
  Speaker 2: but they're not always the most predictive of outcomes. And
• 18:14
  Speaker 2: that's really what we're using these tests to do, is
• 18:16
  Speaker 2: to tell us where are we going, what is our
• 18:18
  Speaker 2: trajectory for health? And so even though we do estimate
• 18:20
  Speaker 2: tela our link, we don't prioritize it nearly as much
• 18:23
  Speaker 2: as some of those biological clocks.
• 18:25
  Speaker 1: Oh okay, I didn't know that, because doctor Lawrence still
• 18:29
  Speaker 1: requires that as a baseline for the clinical trials for
• 18:33
  Speaker 1: getting into his clock trials for the peptid bioregulators. That
• 18:37
  Speaker 1: as you know, he's got about one hundred medical professionals
• 18:41
  Speaker 1: and some even consumers in his clinical trials. But the
• 18:45
  Speaker 1: first thing he does is it makes them take your test.
• 18:48
  Speaker 1: And I can say this from firsthand experience because I
• 18:52
  Speaker 1: am in his trial. But I think I told you that.
• 18:54
  Speaker 1: But then the second one is the spectro cell test,
• 18:59
  Speaker 1: which he made I took twice. But he says he's
• 19:04
  Speaker 1: not so keen on the results of the spectra cell test.
• 19:08
  Speaker 1: He's not so sure about the efficacy. So he may
• 19:12
  Speaker 1: be on the same path as you that maybe that
• 19:14
  Speaker 1: isn't the most important baseline. But what else would he
• 19:17
  Speaker 1: substitute if he didn't do your test? And or does
• 19:21
  Speaker 1: he just need to do your test now because it's
• 19:23
  Speaker 1: so comprehensive.
• 19:25
  Speaker 2: Yeah, Well, you know, at the end of the day,
• 19:27
  Speaker 2: there are a million different measurements for aging, right, and
• 19:30
  Speaker 2: that's because so many different things changes we age. You know,
• 19:33
  Speaker 2: some people like to just use grip strength right o
• 19:37
  Speaker 2: reduced as we age, and so ultimately that whenever we're
• 19:40
  Speaker 2: talking about the testing that we want to use, there's
• 19:42
  Speaker 2: really only two things that are important. I. You know,
• 19:45
  Speaker 2: with all the complication that's out there, I always try
• 19:48
  Speaker 2: and just drill down to two important things. The first
• 19:50
  Speaker 2: is what is the most predictive because ultimately, again that's
• 19:54
  Speaker 2: what we're trying to do, is we're trying to use
• 19:55
  Speaker 2: the test which gives us the most confidence about ar trajectory,
• 19:59
  Speaker 2: right if we're aging orally we want to change that.
• 20:02
  Speaker 2: So you need a test that's been validated to be
• 20:05
  Speaker 2: predictive of outcomes, right, And so generally what that means
• 20:08
  Speaker 2: is you have to take basically data from biobanks. So
• 20:12
  Speaker 2: biobanks have taken samples for years. So we work a
• 20:16
  Speaker 2: lot with Harvard's biobank, which has taken samples for over
• 20:19
  Speaker 2: fifty years, and so we can actually pull samples from
• 20:22
  Speaker 2: fifty years ago, do their epigenetics, and then see if
• 20:25
  Speaker 2: our algorithms are predictive of outcomes. And so you know,
• 20:29
  Speaker 2: our clock's perform very very well. Here. We actually can
• 20:31
  Speaker 2: predict death within a five year time period with a
• 20:34
  Speaker 2: ninety two percent accuracy. So generally all of our algorithms
• 20:38
  Speaker 2: are published, they're well validated. Some of our algorithms have
• 20:41
  Speaker 2: been published over now two hundred and fifty different studies
• 20:44
  Speaker 2: showing all these outcomes with some of the best researchers
• 20:46
  Speaker 2: in the world at your institutions like Harvard, Yale, Duke,
• 20:50
  Speaker 2: you know, Stanford, Columbia, and so there's really really good
• 20:54
  Speaker 2: data to show that these are the most predictive of outcomes,
• 20:57
  Speaker 2: and that's really ultimately why we're using But the second
• 21:00
  Speaker 2: thing that we also want to know is, you know,
• 21:02
  Speaker 2: just getting an idea of where you're at is helpful,
• 21:05
  Speaker 2: but it's not helpful if you don't know how to
• 21:07
  Speaker 2: change it. The other part is is the how what
• 21:11
  Speaker 2: do we know about changing these markers? And that's been
• 21:14
  Speaker 2: someplace that has been hard to do over the past
• 21:17
  Speaker 2: few years, but now has grown exponentially. We can now
• 21:21
  Speaker 2: offer a lot of different recommendations, and we do that
• 21:24
  Speaker 2: through things like our system's age score, where we don't
• 21:27
  Speaker 2: just now give you an age, we actually give you
• 21:28
  Speaker 2: an age of your different organ systems, so we can
• 21:30
  Speaker 2: tell you the age of your you know, your liver
• 21:33
  Speaker 2: versus your brain versus your heart gives us the ability
• 21:36
  Speaker 2: to actually take personalized interventions.
• 21:39
  Speaker 1: So when the test that you're going out, do you
• 21:42
  Speaker 1: actually tell people that when they're going to die within
• 21:46
  Speaker 1: five years? So? Or is that something too too negative
• 21:49
  Speaker 1: to put into a test.
• 21:51
  Speaker 2: Yeah, we we don't put it into the test. You know,
• 21:53
  Speaker 2: the moral implications of that are a little scary, exactly,
• 21:57
  Speaker 2: but we do show that. So the clock that we
• 22:00
  Speaker 2: did to do that is when we created with Harvard.
• 22:02
  Speaker 2: It's called our only Age clock, and it is very
• 22:05
  Speaker 2: very very predictive of lifespan. And so instead of reporting
• 22:08
  Speaker 2: on death, we give you just a biological age, So
• 22:12
  Speaker 2: we tell you how it relates to your chronological age,
• 22:14
  Speaker 2: and ideally your biological age should be lower than your
• 22:17
  Speaker 2: chronological age. That's what we want to achieve for.
• 22:19
  Speaker 1: So what's the average that you see in the tests?
• 22:23
  Speaker 2: Yeah, so it depends on what group we're looking at, right.
• 22:27
  Speaker 2: You know, in our commercial cohort, the people who take
• 22:30
  Speaker 2: our tests commercially, a lot of them do really well
• 22:33
  Speaker 2: on aging. And that's because you know, they're they're most
• 22:37
  Speaker 2: of the people who buyer test are health conscious, right,
• 22:39
  Speaker 2: already self selected to be very interested. But if we
• 22:42
  Speaker 2: look at like biobank cohorts. You know, the general population generally,
• 22:48
  Speaker 2: you know, chronological age is about average, right, chronological and
• 22:52
  Speaker 2: biological age. So what we really want, though, is for
• 22:54
  Speaker 2: everyone to be lower, and so we're trying to get
• 22:57
  Speaker 2: everyone to be as low as possible for as long
• 22:59
  Speaker 2: as we possible.
• 23:01
  Speaker 1: So okay, so on that first category, what would be
• 23:03
  Speaker 1: average be how much younger uh, the biological age cohort
• 23:08
  Speaker 1: than the chronological.
• 23:10
  Speaker 2: Yeah, are our commercial cohort, the one that is probably
• 23:13
  Speaker 2: healthier than any other group out there, is on average
• 23:16
  Speaker 2: about three years younger ch biologically than chronologically, which doesn't
• 23:20
  Speaker 2: sound like a lot, but it actually is. It's a
• 23:22
  Speaker 2: it's a you know, it's a big difference. We're talking
• 23:24
  Speaker 2: about reductions in relative risk that are significant in terms
• 23:28
  Speaker 2: of uh, you know, time until death and a lot
• 23:31
  Speaker 2: of others. And you know, we even have a website
• 23:34
  Speaker 2: called the Rejuvenation Olympics that we created with Brian Johnson,
• 23:37
  Speaker 2: which is sort of a competitive leader board for all
• 23:40
  Speaker 2: the best agers in the world. And so so that
• 23:44
  Speaker 2: that would give you sort of even the top ten agers,
• 23:46
  Speaker 2: who's aging the best in the entire world out of
• 23:48
  Speaker 2: anyone who's taking this.
• 23:49
  Speaker 1: Oh, that's cool. So what what what that website be?
• 23:53
  Speaker 2: So yeah, it's called the Rejuvenation Olympics. I might even
• 23:55
  Speaker 2: just share my screen really quickly. Yeah, sure, show it
• 23:58
  Speaker 2: to you. But this is the one we create with Brian.
• 24:00
  Speaker 2: You know, Brian started the leaderboard but has fell off
• 24:05
  Speaker 2: a couple times and now it's back on top. So
• 24:07
  Speaker 2: his we do this do need and Pace, which was
• 24:09
  Speaker 2: created with Duke. It is your instantaneous pace of aging.
• 24:13
  Speaker 2: And so really Brian got his as the lowest I've
• 24:16
  Speaker 2: ever seen to basically point five. So for every one year,
• 24:21
  Speaker 2: he's only aging half a year in his pace, which
• 24:24
  Speaker 2: is super impressive. We had a couple other celebrities and
• 24:27
  Speaker 2: people on this at one point in time. Another very
• 24:31
  Speaker 2: popular podcaster or YouTuber is sim Land as well. But
• 24:35
  Speaker 2: there's a lot of people on here that are aging
• 24:37
  Speaker 2: very very well. And so this is our leader board.
• 24:41
  Speaker 2: Anyone who takes our tests is able to add their
• 24:44
  Speaker 2: results here and see if they can make it. We
• 24:46
  Speaker 2: do require three tests though, to make this leaderboard.
• 24:49
  Speaker 1: Oh cool, can you shend me as a link to that?
• 24:51
  Speaker 2: Yeah, certainly I want to put.
• 24:53
  Speaker 1: That in the show notes, so yeah, send me that link.
• 24:56
  Speaker 1: That's really cool for people to shave. Well, well, I
• 24:59
  Speaker 1: feel good then because I didn't get to do it
• 25:02
  Speaker 1: really in depth of my result, but it did say
• 25:05
  Speaker 1: ten years. Yeah, difference between biological So that's that's a
• 25:09
  Speaker 1: really good result. Then.
• 25:10
  Speaker 2: Huh oh, that's an incredible result. That's something to be
• 25:13
  Speaker 2: proud of.
• 25:13
  Speaker 1: And I wasn't even that cool about it. I thought,
• 25:16
  Speaker 1: oh no, because at a four am I did a
• 25:18
  Speaker 1: test that told me I was twenty years. So I
• 25:21
  Speaker 1: was a little disappointed. But now after talking to you
• 25:23
  Speaker 1: this morning, I'm feeling much better about that.
• 25:27
  Speaker 2: Definitely. Yeah.
• 25:28
  Speaker 1: Well, I promised that we would make this into a tutorial.
• 25:31
  Speaker 1: Oh one other question before we get into that DNA methylation.
• 25:35
  Speaker 1: A lot of people don't understand what that is. Can
• 25:37
  Speaker 1: you elaborate?
• 25:39
  Speaker 2: Yeah, So, basically, if people are familiar with DNA, they
• 25:42
  Speaker 2: know we have four base pairs of DNA and one
• 25:47
  Speaker 2: of those base pairs is called the cytosine, and at
• 25:51
  Speaker 2: certain parts in our DNA, those cytazines can become methylated.
• 25:54
  Speaker 2: So we basically just attach a carbon group to them,
• 25:57
  Speaker 2: and that's what DNA methylation is, sort of a marker
• 26:00
  Speaker 2: on a cytosine. And again, when that marker is attached. Generally,
• 26:04
  Speaker 2: that gene is less transcribed into RNA, so it's just
• 26:08
  Speaker 2: less active, it's less expressed. And so that's what we're
• 26:11
  Speaker 2: reading actually, is we're looking at your cyitazines in your
• 26:13
  Speaker 2: DNA and seeing how often or not they are actually
• 26:16
  Speaker 2: methylated with that carbon group or not. And the more methilated, again,
• 26:20
  Speaker 2: the less active they are. And so that's really the
• 26:22
  Speaker 2: raw data that we're reading is we're looking at gene
• 26:25
  Speaker 2: locations and we're saying, on a scale of you know,
• 26:27
  Speaker 2: zero to one, what percentage of those citazines are methylated,
• 26:31
  Speaker 2: and how do.
• 26:32
  Speaker 1: You improve that ratio or that that score.
• 26:35
  Speaker 2: Well, then that's the important thing is that that sometimes
• 26:38
  Speaker 2: you want that methylation to be very high. Sometimes you
• 26:40
  Speaker 2: want it to be low. So we're talking about a
• 26:42
  Speaker 2: tumor suppressor gene, we really want that DNA methylation to
• 26:46
  Speaker 2: be really low, right, because then you're actively suppressing tumors.
• 26:50
  Speaker 2: But if we're talking about an oncogene, a gene that
• 26:52
  Speaker 2: might cause cancer, we might want that to be more methylated.
• 26:55
  Speaker 2: And so so it's not necessarily that one is good
• 26:58
  Speaker 2: or bad. It's it's that we want to basically be
• 27:00
  Speaker 2: able to read the pattern instill optimal health outcome. And
• 27:03
  Speaker 2: that's really what we're doing is by training these algorithms
• 27:05
  Speaker 2: to be predictive of things like disease or death, we
• 27:08
  Speaker 2: know what is bad and we know what is good,
• 27:11
  Speaker 2: and then we can tell you where you're at on
• 27:12
  Speaker 2: that spectrum.
• 27:13
  Speaker 1: So just personal question to you for a moment, when
• 27:16
  Speaker 1: you did your chest how did you change your results?
• 27:19
  Speaker 1: What were some of the lifestyle things that you did
• 27:23
  Speaker 1: that you can now see have made a difference. Oh.
• 27:25
  Speaker 2: Yeah, we've done a little bit of everything. Actually, So
• 27:28
  Speaker 2: at this point in time, we've done now over one
• 27:30
  Speaker 2: hundred and twenty interventional trials, So we've done we've done
• 27:33
  Speaker 2: trials and everything from stem cells to exosomes to hyperbaric
• 27:37
  Speaker 2: oxygen to you know, retroviral inhibitors to GLP ones and
• 27:41
  Speaker 2: weight loss medications. So we've got data on all of these. Personally,
• 27:45
  Speaker 2: I try a lot as well, on sort of my
• 27:47
  Speaker 2: own guinea pig, and I think that, you know, we
• 27:49
  Speaker 2: have different things that work for everyone. I tend to
• 27:51
  Speaker 2: be a really big fan of the tried and true methods,
• 27:55
  Speaker 2: and I know that this is not exciting for anyone,
• 27:57
  Speaker 2: but things like exercise, things like stress production, things like
• 28:01
  Speaker 2: plant based diets with you know, are very particularly green,
• 28:05
  Speaker 2: Mediterranean diets or excellent. But we've now even published with
• 28:08
  Speaker 2: Yale on over fifty one different age interventions and rank
• 28:11
  Speaker 2: them all together. And so some of the more exotic
• 28:14
  Speaker 2: things that I really like are things like hyperbaric. Hyperbaric
• 28:18
  Speaker 2: is one of the biggest signals that we've seen in
• 28:21
  Speaker 2: healthy populations. I also am a very big fan of
• 28:24
  Speaker 2: things of like the s g l T two inhibitors
• 28:28
  Speaker 2: sort of like your canagula flows in or impagala flows
• 28:31
  Speaker 2: and that make your kidneys permeable to glucose, so you
• 28:34
  Speaker 2: sort of pee out your glucose. I'm a really big
• 28:37
  Speaker 2: fan of those as well. So, but we've got now
• 28:39
  Speaker 2: a lot of data, and that's really the idea is
• 28:41
  Speaker 2: that we can start to benchmark what are the best
• 28:43
  Speaker 2: interventions for every single person.
• 28:45
  Speaker 1: Oh, that's so amazing. It's just getting more and more finite.
• 28:49
  Speaker 2: Yeah, it is, and that makes people can.
• 28:51
  Speaker 1: Make better choices, because you know, it is daunting for
• 28:56
  Speaker 1: a patient to look at these results and say, well,
• 28:59
  Speaker 1: where to start and how do you know, if I'm
• 29:02
  Speaker 1: already living a very healthy lifestyle, how do I get
• 29:04
  Speaker 1: to that more finite level that's going to make the
• 29:08
  Speaker 1: difference in these results. So this is really important Ryan,
• 29:12
  Speaker 1: what you're doing.
• 29:13
  Speaker 2: Oh, and that's sort of the vision is that we
• 29:15
  Speaker 2: think that from an aging perspective, we can start to
• 29:18
  Speaker 2: look at all of these aging interventions with the same
• 29:20
  Speaker 2: measuring stick, right, and then then be able to say, again,
• 29:24
  Speaker 2: the tool that's the most predictive of outcomes is the
• 29:26
  Speaker 2: most reversed by different diet types or different different interventions.
• 29:31
  Speaker 2: And so that's really the idea is at the end
• 29:33
  Speaker 2: of the day, that's really what we want to do
• 29:35
  Speaker 2: is give people actionable information to reverse or slow their
• 29:38
  Speaker 2: aging process, which is the biggest respector for every disease.
• 29:41
  Speaker 2: And so it's a really really science driven endeavor. You know,
• 29:45
  Speaker 2: we're doing a lot of publications, a lot of collaborations,
• 29:49
  Speaker 2: but ultimately we want to take the guesswork out of it.
• 29:52
  Speaker 1: And are you doing any clinical trials like Harvard ged
• 29:55
  Speaker 1: and you can show I know you're doing joint bens
• 30:00
  Speaker 1: with them, but are you as true diagnostics are you
• 30:02
  Speaker 1: taking people in like myself if I wanted to join
• 30:06
  Speaker 1: a trial? Oh?
• 30:07
  Speaker 2: Absolutely, we do this all the time. We've done you know,
• 30:12
  Speaker 2: studies on a variety of different things right now. Actually,
• 30:15
  Speaker 2: we're submitting we just submitted a grant. Were selected as
• 30:18
  Speaker 2: one of the final three applications to get an actual
• 30:21
  Speaker 2: FDA approved test for aging by the government, and so
• 30:24
  Speaker 2: we're building an interventional trial of over twelve hundred people
• 30:28
  Speaker 2: that should go in about a year and hopefully we'll
• 30:30
  Speaker 2: have the first ever FDA approved test for aging.
• 30:33
  Speaker 1: Can you put me on that list?
• 30:35
  Speaker 2: Yeah, certainly. It's gonna be a fun one and we
• 30:38
  Speaker 2: feel very very good about it.
• 30:40
  Speaker 1: I would love to do that. Yeah, I think, you know,
• 30:42
  Speaker 1: being right in the heart of the science when you're
• 30:46
  Speaker 1: looking at all these lifestyle issues. I mean, for example,
• 30:50
  Speaker 1: people like you have on the Brian Johnson website, there
• 30:55
  Speaker 1: are people who are already devoted to improving their health.
• 31:00
  Speaker 1: Maybe not as extreme as Brian Johnson with two million
• 31:02
  Speaker 1: dollars budget a year and eating his last meal at
• 31:06
  Speaker 1: eleven am. I mean, that's you know, for most people,
• 31:09
  Speaker 1: that's pretty outrageous and extreme. However, the normal, you know,
• 31:13
  Speaker 1: average person that is still showing up on that list
• 31:18
  Speaker 1: is already committed to having a healthy lifestyle. Yet they
• 31:23
  Speaker 1: could still get tests like I did today that show
• 31:26
  Speaker 1: a lot of areas of improvement. And then you look
• 31:28
  Speaker 1: at the tests and you say, but I'm already doing that.
• 31:31
  Speaker 1: I'm already taking D two and K three, I'm already
• 31:34
  Speaker 1: doing vitamin B complex, and yet the test comes out
• 31:39
  Speaker 1: with some scores that are questionable. So then the question
• 31:42
  Speaker 1: for the consumer or the patient is what do I do?
• 31:45
  Speaker 1: How do I do the next step to improve what
• 31:50
  Speaker 1: I am already thinking I'm doing that should have produced
• 31:53
  Speaker 1: a better result. So what do you say to those people?
• 31:57
  Speaker 2: Yeah, you know, so I think maybe now a good
• 32:00
  Speaker 2: time to even go into what you get. Maybe, yeah,
• 32:02
  Speaker 2: if you actually see some of our results, because.
• 32:04
  Speaker 1: Yeah, I want that was my That was going to
• 32:07
  Speaker 1: be the next segue, but I just thought it would
• 32:08
  Speaker 1: be good for people to understand that again, like the
• 32:11
  Speaker 1: genetics testing, don't don't look at this as a death sentence.
• 32:15
  Speaker 1: And just because your result is lower, it doesn't mean
• 32:20
  Speaker 1: that that you can't there's still not room for improvement
• 32:23
  Speaker 1: even though you're already doing Like I take a thousand
• 32:26
  Speaker 1: milligrams of D three and then I take whatever four hundred,
• 32:29
  Speaker 1: five hundred K two, and they're in a combination of
• 32:32
  Speaker 1: I think it's thorn or pure encapsulation so they're a
• 32:35
  Speaker 1: good company. And yet still you know, the test result
• 32:39
  Speaker 1: may have come out a bit lower than what I
• 32:41
  Speaker 1: would have expected, given that I'm already supplementing. So those
• 32:45
  Speaker 1: kinds of things and what I want you to cover
• 32:47
  Speaker 1: when you go over these results that just keep in
• 32:50
  Speaker 1: mind people don't want to get discouraged.
• 32:52
  Speaker 2: Yeah, certainly, certainly, And and you know they're they're for
• 32:56
  Speaker 2: our tests. There are really only two tests that we do.
• 32:58
  Speaker 2: The first test is are a bio logical age tester,
• 33:00
  Speaker 2: which we'll be talking a lot about today. So this
• 33:04
  Speaker 2: is the first one to go over because again, you know,
• 33:06
  Speaker 2: biological age is the biggest risk for every chronic disease,
• 33:09
  Speaker 2: and so we say there's one thing that you want
• 33:11
  Speaker 2: to prioritize. It's your biggest risk factor, right hey, And
• 33:14
  Speaker 2: so ultimately this this you know, we have three big
• 33:17
  Speaker 2: aging algorithms that we use here on this one this
• 33:20
  Speaker 2: is our only age. Again, we tell you where your
• 33:22
  Speaker 2: chronological ages versus calendar age. We tell you where you're
• 33:25
  Speaker 2: at within our population, and we can even track those
• 33:28
  Speaker 2: results over time.
• 33:29
  Speaker 1: Okay, okay, let me let me let you take over
• 33:32
  Speaker 1: the podcast. This is your your opportunity now to have
• 33:37
  Speaker 1: people understand exactly what they're going to get in this
• 33:41
  Speaker 1: amazing test, which is not something that most people are
• 33:46
  Speaker 1: used to. You know, they go and do a blood
• 33:48
  Speaker 1: work test maybe once a year, and you know, maybe
• 33:51
  Speaker 1: some specialty test, but never ever is there a test
• 33:55
  Speaker 1: that that I know of that is this comprehensive that
• 33:58
  Speaker 1: will tell you so much. So let me let it
• 34:01
  Speaker 1: be your game right now to tell everybody what this
• 34:03
  Speaker 1: is all about.
• 34:04
  Speaker 2: So go ahead, thanks of y'all, try and make it
• 34:06
  Speaker 2: as quick as possible just so everyone can get an
• 34:08
  Speaker 2: overview and then we can talk about how you use
• 34:10
  Speaker 2: it right and the fun part. But yeah, this only
• 34:13
  Speaker 2: age is one of our algorithms. Again, we can even
• 34:15
  Speaker 2: tell you how your age is increasing your risk of
• 34:17
  Speaker 2: every other disease because again we have these outcomes. We've
• 34:20
  Speaker 2: actually measured this in people who have gone on thirty
• 34:23
  Speaker 2: years or forty years, and we actually know what their
• 34:26
  Speaker 2: risk of developing these diseases were, And then we can
• 34:28
  Speaker 2: actually even tell you what's high or low. So we
• 34:30
  Speaker 2: can actually tell you, you know, what's driving your aging process.
• 34:33
  Speaker 2: So is it glucose, maybe your insulin resistance, or is
• 34:37
  Speaker 2: it your lipids, or is it inflammation we can actually
• 34:40
  Speaker 2: start to point out to what's out of range here
• 34:42
  Speaker 2: and then even make some specific recommendations. So that's what
• 34:45
  Speaker 2: we call our own gauge we develop with Harvard. We
• 34:47
  Speaker 2: also have our Symphony Age. This is one we develop
• 34:49
  Speaker 2: with the researchers at Yale that actually gives you the
• 34:52
  Speaker 2: age of each organ system, so your lung versus metabolic
• 34:55
  Speaker 2: versus muscular, skeletal, and again this helps us give more
• 34:58
  Speaker 2: precise recommendations. You know, someone who's a smoker, for instance,
• 35:01
  Speaker 2: might have really high inflammation where they might have really
• 35:04
  Speaker 2: high lung age, but someone who's maybe overweight might have
• 35:07
  Speaker 2: metabolic aging, and so we can actually now start to
• 35:10
  Speaker 2: differentiate for individual system recommendations. And so this was a
• 35:13
  Speaker 2: big step forward and we just had this now we've
• 35:16
  Speaker 2: only had it for about a year on the platform.
• 35:19
  Speaker 2: And then you know, we also have probably everyone's favorite,
• 35:22
  Speaker 2: which is the duned and pace and so that's that
• 35:24
  Speaker 2: rate of aging we had on the Rejuvenation Olympics website
• 35:26
  Speaker 2: that tells you how fast you're aging right at this moment.
• 35:29
  Speaker 2: The reason that people like this one the most is
• 35:31
  Speaker 2: because it's one of the most well validated, but it's
• 35:33
  Speaker 2: also the most correlated to health span related metrics. So
• 35:37
  Speaker 2: a lot of people think, you know, I don't want
• 35:39
  Speaker 2: to live, you know, till I'm one hundred and twenty
• 35:41
  Speaker 2: and just have a really poor quality of life. And
• 35:43
  Speaker 2: so if you really want to maximize things like your
• 35:45
  Speaker 2: IQ and mental processing speeds, even your facial aging, it's
• 35:49
  Speaker 2: really tied to this metric. And so for people they
• 35:52
  Speaker 2: really like this, it's also more responsive to change. And
• 35:55
  Speaker 2: so again we want this to be as low as possible.
• 35:57
  Speaker 2: Well again, Brian's is the lowest we've ever seen in
• 35:59
  Speaker 2: a point five, but you know, as long as you're
• 36:02
  Speaker 2: below one, that's really what we want to see there.
• 36:04
  Speaker 2: And so those are some of the biggest aging metrics,
• 36:06
  Speaker 2: but we do a lot of other things on this
• 36:08
  Speaker 2: report too. We can tell you all about your immune subsets,
• 36:12
  Speaker 2: you know, to see if you have any immune deficiencies.
• 36:14
  Speaker 2: We do tell you your telomere length here as well,
• 36:17
  Speaker 2: and we can even do things like telling you how
• 36:19
  Speaker 2: much you smoke or drink across a lifetime based on
• 36:22
  Speaker 2: these markers. And so so that's really what our true
• 36:25
  Speaker 2: age report looks like, and it's really meant to quantify
• 36:27
  Speaker 2: that aging process. And and again There are a lot
• 36:30
  Speaker 2: of different age tests out there, but these.
• 36:32
  Speaker 4: Biological clocks are all validated, they're all published, They've been
• 36:36
  Speaker 4: compared to interventional trials, so you know what changes them,
• 36:38
  Speaker 4: and they provide a lot of really science based sort
• 36:41
  Speaker 4: of feedback for you on the aging process.
• 36:45
  Speaker 1: I apologize I didn't see the killing mirror length and
• 36:48
  Speaker 1: myke kesh, so I did say that I didn't see
• 36:51
  Speaker 1: it this time, but I guess it is there, so
• 36:53
  Speaker 1: I'll go back and look at that for the one.
• 36:57
  Speaker 2: And yeah, but you know, the next thing I want
• 37:00
  Speaker 2: to introduce is actually something a little bit different. It's
• 37:03
  Speaker 2: our other report. We actually call our true Health Report.
• 37:06
  Speaker 2: You don't mind, I'd love to explain this a little
• 37:08
  Speaker 2: bit more because this is one of the biggest surprises
• 37:11
  Speaker 2: that we had at our company. You know, whenever we
• 37:14
  Speaker 2: wanted to create the omic age, we noticed one big thing,
• 37:17
  Speaker 2: which is if we wanted to create the best aging
• 37:18
  Speaker 2: clock available, we really needed the most data available and
• 37:22
  Speaker 2: so we really wanted to measure everything we could possibly
• 37:25
  Speaker 2: measure in this cohort, and so in order to do that,
• 37:28
  Speaker 2: we have this classification system we call the multi home
• 37:31
  Speaker 2: and it really starts with genomics right, what is that
• 37:34
  Speaker 2: DNA sequence. Then it goes to epigenomics and that is
• 37:37
  Speaker 2: again what DNA's expressed, what's turned on and turned off.
• 37:40
  Speaker 2: That then creates RNA, which is transcriptomics. That RNA then
• 37:44
  Speaker 2: goes to the ribosomes to create peptides and create proteins.
• 37:47
  Speaker 2: That's what we call proteomics. That really creates the infrastructure
• 37:51
  Speaker 2: of the body and then creates metabolites. And so we're
• 37:53
  Speaker 2: talking about hormones, we're talking about neurotransmitters, we're talking about
• 37:57
  Speaker 2: all of the different chemical exposures you might have your environment,
• 38:00
  Speaker 2: like pfoss chemicals or even microplastics, and then ultimately you
• 38:04
  Speaker 2: have the outcome what ended up happening to the person.
• 38:06
  Speaker 2: And so we took all of this data that we
• 38:08
  Speaker 2: possibly could and measure this in our Harvard cohort. The
• 38:12
  Speaker 2: problem is it's really expensive to measure all of these
• 38:15
  Speaker 2: different things and so and you also need plasma, you
• 38:19
  Speaker 2: need phlebotomy, and so we basically asked the question, can
• 38:22
  Speaker 2: we just with methylation predict all of these other values?
• 38:26
  Speaker 2: So can we predict your hormone levels? Can we predict
• 38:29
  Speaker 2: your neurotransmitters and cortisol? Can we predict your clinical function
• 38:32
  Speaker 2: measurements like your VO two max or your HbA one C,
• 38:36
  Speaker 2: and the answer was yes, we actually could. We can
• 38:39
  Speaker 2: actually do this with seventeen hundred different bio markers just
• 38:42
  Speaker 2: from DNA methylation. And one of the coolest things about
• 38:45
  Speaker 2: this is that they actually tend to be more predictive
• 38:48
  Speaker 2: of outcomes than even your classical biomarkers. And so this
• 38:53
  Speaker 2: is when we created this report we're calling True Health,
• 38:55
  Speaker 2: and we actually think that in the next few years
• 38:58
  Speaker 2: this will replace all of your clinic blood testing. There's
• 39:01
  Speaker 2: reason you'll need to go to a lab core request
• 39:03
  Speaker 2: to get your bloods drawn because we can actually report
• 39:06
  Speaker 2: on all of these different things that you would see here.
• 39:09
  Speaker 2: And so you know, in terms of categories, we do
• 39:11
  Speaker 2: a lot. We do all of your vitamins, so all
• 39:13
  Speaker 2: of your B vitamins, your ad E K vitamins. We
• 39:16
  Speaker 2: would do all of your amino acids like your you know,
• 39:19
  Speaker 2: taurine or or gathionine, which we know is a great
• 39:22
  Speaker 2: longevity specific amino acid. You know. In addition to that,
• 39:27
  Speaker 2: we can do all of your antioxidants like your carotenoids.
• 39:29
  Speaker 2: We can do your fats and cellular membranes like your
• 39:32
  Speaker 2: Omega three ratios, your Mega six ratios. We can even
• 39:35
  Speaker 2: tell you about, you know, your NAD bio markers, your
• 39:39
  Speaker 2: lipid particle sizes. You know, we can get so much
• 39:42
  Speaker 2: information now from just a single drop of blood and
• 39:46
  Speaker 2: running all of these different algorithms on it, and again
• 39:49
  Speaker 2: they are more predictive sixty two percent of the time.
• 39:51
  Speaker 2: They're more predictive of the classical bio markers. So for instance,
• 39:55
  Speaker 2: you know, if we're trying to put a cardivascuar disease,
• 39:57
  Speaker 2: a lot of people look at blood pressure, but our
• 39:59
  Speaker 2: prediction of blood pressure through epigenetics is actually better than
• 40:03
  Speaker 2: even the measured blood pressure that you get in clinic
• 40:05
  Speaker 2: in terms of predicting cardiovascu disease. Yeah. So one of
• 40:10
  Speaker 2: the reasons we think that this is the case is
• 40:11
  Speaker 2: I always like to use a Steve Horbath quote. Which
• 40:14
  Speaker 2: is another potential benefit of using DNA methylation based bio
• 40:18
  Speaker 2: markers is they represent a longer average concentration. So the
• 40:22
  Speaker 2: best similar example is HbA, W and C and fast
• 40:25
  Speaker 2: and glucose. Right, our fast and glucose can vary all
• 40:29
  Speaker 2: throughout the day, and if we get it at a
• 40:30
  Speaker 2: single point in time, it might not be indicative of
• 40:32
  Speaker 2: our overall health. Right, we might have just had a
• 40:35
  Speaker 2: you know, a big glucose meal, right, And ours is
• 40:38
  Speaker 2: super high doesn't mean we have diabetes. It just means
• 40:40
  Speaker 2: that our glucose is high at that moment. HbA, W
• 40:43
  Speaker 2: and C is a three month running average of our
• 40:45
  Speaker 2: glucose levels, and so it gives us a much better
• 40:48
  Speaker 2: idea of what our overall glucose is. And so if
• 40:51
  Speaker 2: the same is true with these DNA methylation bio markers,
• 40:54
  Speaker 2: is that we're getting a longer average and therefore it's
• 40:57
  Speaker 2: more predictive of outcomes than even just a single point
• 41:01
  Speaker 2: in time measure. And so yeah, again we published with
• 41:04
  Speaker 2: you know a lot of really good data here I
• 41:06
  Speaker 2: can show, but we publish with Harvard that again sixty
• 41:09
  Speaker 2: two percent of the time our bio markers are better
• 41:12
  Speaker 2: than the classical measures. But again, we don't have to
• 41:14
  Speaker 2: get a whole blood. We don't have to, so we
• 41:17
  Speaker 2: don't have to go to for bottomus. We don't have
• 41:19
  Speaker 2: We get over seventeen hundred of these bio markers from
• 41:22
  Speaker 2: a single drop of blood, and so the scale and
• 41:25
  Speaker 2: inaccuracy and predictability of these things is sort of incredible,
• 41:28
  Speaker 2: and that goes into this report where we actually tell
• 41:30
  Speaker 2: you again where you're at, what your what your if
• 41:33
  Speaker 2: your HDL particle size is high, if it's low, and
• 41:36
  Speaker 2: then we try and give you recommendations on how to
• 41:37
  Speaker 2: improve that. Some of the things we can do here
• 41:40
  Speaker 2: are pretty incredible. You know. We can tell you even
• 41:43
  Speaker 2: what you're eating based on these different metabolites and then
• 41:46
  Speaker 2: even suggests ways to improve that. I always so I'll
• 41:50
  Speaker 2: show you maybe one more example if you don't mind,
• 41:52
  Speaker 2: one of my favorites, which is that we can actually,
• 41:56
  Speaker 2: you know, again look at what you're eating based on
• 41:58
  Speaker 2: the metabolites and your blood. So you know, we did
• 42:01
  Speaker 2: this by taking self reported food behaviors and linking them
• 42:04
  Speaker 2: to metabolites, and then we can do a network analysis
• 42:07
  Speaker 2: where we can actually tell you what metabolites are linked
• 42:09
  Speaker 2: to what foods, and so we can actually tell you
• 42:12
  Speaker 2: what you're eating now based on this testing, and then
• 42:15
  Speaker 2: we can actually apply it. So this is our only
• 42:16
  Speaker 2: gauge algorithm. The things on here that you see on
• 42:19
  Speaker 2: the left are the foods which are at best for
• 42:21
  Speaker 2: this aging versus the foods on the right which are
• 42:23
  Speaker 2: worse and so we see things like fish, you know,
• 42:26
  Speaker 2: eggs and mushrooms being really good for the aging process,
• 42:29
  Speaker 2: and on those side we see things like sweet and
• 42:31
  Speaker 2: foods and beverages, cereals and processed foods being really bad,
• 42:35
  Speaker 2: which again is pretty intuitive, but we can actually read
• 42:37
  Speaker 2: this all through your DNA methylation profiles, and so it's
• 42:41
  Speaker 2: really incredible the amount of information we can get from this.
• 42:44
  Speaker 2: There are multiple case use examples, but again, just from
• 42:48
  Speaker 2: a single drop of blood, we can tell you all
• 42:49
  Speaker 2: of this information.
• 42:51
  Speaker 1: Oh so, Ryan, was all that in the chest that
• 42:56
  Speaker 1: you set me today?
• 42:57
  Speaker 2: Not yet. So the food and diet things will be
• 43:00
  Speaker 2: on our future tests. And again we're even adding the
• 43:04
  Speaker 2: ability to predict disease, so we'll be able to tell
• 43:06
  Speaker 2: you your five and ten year risk for things like
• 43:08
  Speaker 2: Alzheimer's or Cardivasker disease or diabetes. Right now, it's not commercialized.
• 43:12
  Speaker 2: It needs a little bit more research and development before
• 43:14
  Speaker 2: we roll it out.
• 43:14
  Speaker 1: And what about hormones. I don't see like I know
• 43:18
  Speaker 1: that you're going to be focusing on hormones at some point.
• 43:21
  Speaker 2: Yeah, you know, hormones are obviously super important as we
• 43:23
  Speaker 2: talk about aging. Unfortunately, hormones tend to be one of
• 43:26
  Speaker 2: our big weaknesses at the moment. You know, people who
• 43:29
  Speaker 2: take exogenous hormones uh sometimes mess up our readings. And
• 43:33
  Speaker 2: so right now, hormones are not on our list of things.
• 43:36
  Speaker 2: We can predict some hormones like thybroid, some like cortisol
• 43:40
  Speaker 2: and cortizone, but we can't do sex hormones right now,
• 43:43
  Speaker 2: like disaster and estro dial.
• 43:45
  Speaker 1: I saw that. I was disappointed, but I say, hey,
• 43:48
  Speaker 1: they've done so much else. But I did you know
• 43:51
  Speaker 1: it was a question. It is a question because the
• 43:53
  Speaker 1: hormones are the super highway of your of your body,
• 43:57
  Speaker 1: of your health. So but you do you do folks
• 44:00
  Speaker 1: us on mitochondrial function. And I noticed though that you're
• 44:05
  Speaker 1: kind of dodged the issue of met forman and some
• 44:08
  Speaker 1: of these that you talked about earlier that you did
• 44:11
  Speaker 1: at Taylor made is there is there a reason for
• 44:14
  Speaker 1: that if you're not giving recommendations for the pharmaceutical side
• 44:19
  Speaker 1: for aging for anti aging.
• 44:23
  Speaker 2: Yeah, you know, so we we're building those data sets
• 44:26
  Speaker 2: right now. You know, a lot of people like to
• 44:28
  Speaker 2: recommend met form and for aging. We're not as certain,
• 44:31
  Speaker 2: you know, the data that we've seen doesn't look as
• 44:33
  Speaker 2: overall compelling. I think, you know, we've done actually met
• 44:37
  Speaker 2: form in an HIV population and it was phenomenal. We
• 44:40
  Speaker 2: had anti aging reductions across the board. But in normal
• 44:44
  Speaker 2: individuals who are who don't have any blood sugar related issues,
• 44:47
  Speaker 2: we don't see the biggest change with met format. Even
• 44:50
  Speaker 2: with the GLP ones. Uh you know, if you're already
• 44:53
  Speaker 2: pretty healthy and you don't have metabolic issues, we don't
• 44:56
  Speaker 2: see a big change with the GLP ones. But if
• 44:59
  Speaker 2: you are metabal luckily unhealthy, we see massive aging reductions
• 45:02
  Speaker 2: in the GLP ones. And so you know, we've booked
• 45:05
  Speaker 2: at everything from rapamyasin to uh you know, med foreman
• 45:09
  Speaker 2: to we just publish a study on statins even and
• 45:13
  Speaker 2: so we're again we're getting all of this data, but
• 45:15
  Speaker 2: right now we're hesitant to recommend, you know, drugs for
• 45:19
  Speaker 2: aging that have been improved in other areas.
• 45:22
  Speaker 1: And what about the peptide? So you know, I noticed
• 45:25
  Speaker 1: in the test that I you know, this morning just
• 45:27
  Speaker 1: reviewing it, and you've made some recommendations of supplements to take,
• 45:31
  Speaker 1: But I don't see anything with the area that you're
• 45:35
  Speaker 1: the most familiar with, which is peptide. So is there
• 45:37
  Speaker 1: a deliberate reason for that.
• 45:39
  Speaker 2: Yeah, it's all based on data. So we will not
• 45:41
  Speaker 2: we will not recommend anything that doesn't have a clear
• 45:45
  Speaker 2: i would say data publication relationship. And unfortunately with the peptides,
• 45:49
  Speaker 2: you know, I'm a huge fan of the peptides. I
• 45:51
  Speaker 2: couldn't say enough positive things about them, but unfortunately they
• 45:54
  Speaker 2: don't have very much studies or data. And a lot
• 45:57
  Speaker 2: of that is because these things are oftentimes their patents
• 46:01
  Speaker 2: have expired, so there's no reason for people to invest
• 46:04
  Speaker 2: in this research. And that's really sad. You know, I've
• 46:07
  Speaker 2: seen you know, most people know even products like you
• 46:11
  Speaker 2: know CJC or ipamorland Is, these growth fromone products. But
• 46:15
  Speaker 2: you know, impen moreland Is has been bought by you know,
• 46:18
  Speaker 2: glax of Smith Klein and and really left and abandoned
• 46:21
  Speaker 2: right on a development pipeline, and so so unfortunately there's
• 46:24
  Speaker 2: not a lot of economic incentive to have these things studied,
• 46:28
  Speaker 2: and so so unfortunately at the moment, there's not a
• 46:30
  Speaker 2: lot of data and therefore we don't make those recommendations
• 46:32
  Speaker 2: without very clear data.
• 46:34
  Speaker 1: Yeah, so this is what's happening then, just similar to
• 46:36
  Speaker 1: what happened with Apple and Google and the others where
• 46:39
  Speaker 1: they would acquire their competitors and then just put them
• 46:43
  Speaker 1: out of business. Basically, is that is that really what's
• 46:45
  Speaker 1: happening now with more from Marellen and soci Smith Clin
• 46:50
  Speaker 1: owns them now.
• 46:51
  Speaker 2: Yeah, so so you know, they're they're all owned by
• 46:53
  Speaker 2: a variety of pharmaceuticals. You know, s S thirty one
• 46:56
  Speaker 2: is owned by Stealth Biopharma. You've got you know, the
• 47:00
  Speaker 2: imus and alpha or zaxin that's owned by Cyclone Therapeutics. Again,
• 47:05
  Speaker 2: and they've really all stopped their development and spending. And
• 47:08
  Speaker 2: so even though they're great products, they you know, it
• 47:11
  Speaker 2: takes two point three billion dollars to go to the
• 47:14
  Speaker 2: FDA and get an approval of a drug. That's a
• 47:16
  Speaker 2: lot of money and very very very few companies throughout
• 47:20
  Speaker 2: the world would have that amount of money. And so
• 47:23
  Speaker 2: just because I think there's a different threshold, But unfortunately
• 47:26
  Speaker 2: we don't have data for those things. You know, we're
• 47:29
  Speaker 2: always trying to get some of that data from our
• 47:31
  Speaker 2: commercial cohort people who are already using them. We can
• 47:34
  Speaker 2: do cross sectional analysis, but we can't do a pacebal
• 47:37
  Speaker 2: control trial because you know, it's really not sponsored or
• 47:41
  Speaker 2: approved in the typical formats.
• 47:44
  Speaker 1: Is this a shame for the chemi glue tides.
• 47:46
  Speaker 2: Sema glue tide is different. You know that that is
• 47:48
  Speaker 2: a you know, owned by nober Nordisk. It goes off
• 47:51
  Speaker 2: patent in twenty twenty seven. And we've actually published two
• 47:54
  Speaker 2: studies on the seama glue tide, one in a healthy
• 47:57
  Speaker 2: population and then one in an HIV population. But we
• 48:01
  Speaker 2: have even created an aborigeneity predicture of weight loss response,
• 48:04
  Speaker 2: so we can actually tell you if you would be
• 48:05
  Speaker 2: a good candidate to lose subcutaneous tissue with that different intervention.
• 48:10
  Speaker 1: Is that a test that you have to take separately
• 48:12
  Speaker 1: to get that info or is that not it's not
• 48:16
  Speaker 1: available yet.
• 48:17
  Speaker 2: It's not available yet. We haven't commercialized it, but we
• 48:19
  Speaker 2: have published on it.
• 48:21
  Speaker 1: Okay, And you're saying that there is going to be
• 48:25
  Speaker 1: a test that you can take to tell you whether
• 48:27
  Speaker 1: a semi glue tide is going to be beneficial for
• 48:30
  Speaker 1: you or not.
• 48:31
  Speaker 2: Yeah. Even beyond that, we'll be able to tell you
• 48:33
  Speaker 2: if you're going to lose muscle or visceral atipus tissue
• 48:36
  Speaker 2: or subcutaneous and we'll tell you if you have side
• 48:38
  Speaker 2: effects like GI side effects or nausea. So so it'll
• 48:42
  Speaker 2: be almost like a companion diagnostic to be able to
• 48:44
  Speaker 2: use to recommend which GLP one you might want to
• 48:47
  Speaker 2: be on.
• 48:47
  Speaker 1: Wow, that's that's just absolutely amazing, given how widespread and
• 48:53
  Speaker 1: how abused this is, this semi gluetide. The GLP ones
• 48:57
  Speaker 1: have become because people have just you know, one, there's
• 49:00
  Speaker 1: so much obesity in this country, that and diabetes that
• 49:03
  Speaker 1: people just want to find anything that will make a change,
• 49:07
  Speaker 1: and sometimes they don't do the research. The doctor isn't
• 49:10
  Speaker 1: as thorough, which just gives them a new prescription and say,
• 49:15
  Speaker 1: you know, come back when you've lost your first ten pounds,
• 49:18
  Speaker 1: and forgetting about the fact that scycopenia is one of
• 49:21
  Speaker 1: the biggest side effects. Not only that, but there are
• 49:24
  Speaker 1: many people reporting other serious side effects like you know,
• 49:28
  Speaker 1: gastro intestinal and nausea and all that. So this is
• 49:31
  Speaker 1: going to be amazing. I mean, so when what's the timeline?
• 49:36
  Speaker 2: Yeah, so, so you know, I think probably just in
• 49:38
  Speaker 2: six months or so we'll be able to have it
• 49:41
  Speaker 2: and to be honest, we might be able at it
• 49:43
  Speaker 2: for free on all of our reports.
• 49:44
  Speaker 1: Oh my goodness, Oh lord.
• 49:47
  Speaker 2: Yeah, what is the cost?
• 49:48
  Speaker 1: What is the cost of the test as it is today?
• 49:52
  Speaker 2: Yeah, so, so generally I think we do each of
• 49:54
  Speaker 2: our reports for around four ninety nine direct for the consumer. However,
• 49:58
  Speaker 2: I think, you know, we always try and give some
• 49:59
  Speaker 2: disc on that, and I think that if anyone's watching this,
• 50:02
  Speaker 2: they can use the coach Ageless twenty for twenty percent
• 50:05
  Speaker 2: off that it would.
• 50:06
  Speaker 1: Be five hundred let's say for each test, so one
• 50:09
  Speaker 1: thousand dollars, so they could get it for eight hundred.
• 50:12
  Speaker 2: Yeah. Well, and actually the combo is, will you offer
• 50:14
  Speaker 2: for a ninety nine again, if you get out twenty
• 50:16
  Speaker 2: percent off, that it'll be even cheaper.
• 50:19
  Speaker 1: So it'll be about seven hundred. Yeah. Wow, everybody listening,
• 50:23
  Speaker 1: I hope and watching today, this is like amazing. It'll
• 50:26
  Speaker 1: be one of the best seven hundred dollars you've ever
• 50:28
  Speaker 1: spent for managing your health. I can say that with
• 50:32
  Speaker 1: all and I'm not even an affiliate with you or
• 50:36
  Speaker 1: you know, there's no financial considerations here. I say this
• 50:40
  Speaker 1: only because I'm a believer and because I want I
• 50:44
  Speaker 1: want to help people, and really I just I'm going
• 50:49
  Speaker 1: to send us test to my doctor you know who
• 50:53
  Speaker 1: my doctor is, and say why am I taking my
• 50:55
  Speaker 1: lab Core tests in August my annual blood work. When
• 51:00
  Speaker 1: you've got this test, do I really even need to go?
• 51:03
  Speaker 1: Is there anything missing on this test? It isn't on
• 51:06
  Speaker 1: the normal, the typical blood work.
• 51:10
  Speaker 2: You know, outside of hormones. Not really, you know, that
• 51:13
  Speaker 2: is at the end of the day, the one thing
• 51:15
  Speaker 2: we're trying to add to make it a comprehensive test.
• 51:17
  Speaker 2: And again even when we compare them head to head,
• 51:20
  Speaker 2: we know that these are actually better than even your
• 51:22
  Speaker 2: classical blood work.
• 51:23
  Speaker 1: Have you had any repercussions from lab Core A quest
• 51:26
  Speaker 1: about the fact.
• 51:27
  Speaker 2: That, Yeah, not yet. We just published the pre print
• 51:30
  Speaker 2: in December, and so this is still very very new.
• 51:32
  Speaker 2: But we're really excited to, you know, to get this
• 51:36
  Speaker 2: more widely used and validated. I think that in the
• 51:38
  Speaker 2: next three months we should have six or seven validation
• 51:41
  Speaker 2: studies coming out showing just how good and predictive these are.
• 51:44
  Speaker 1: So if people just go and do their hormone test,
• 51:47
  Speaker 1: that would be all they would need. Just because I
• 51:51
  Speaker 1: last time I did my blood work, they took twenty
• 51:54
  Speaker 1: vials of blood and she does really comprehensive lab work.
• 51:59
  Speaker 1: So uh well, I guess we'll do it this year
• 52:02
  Speaker 1: just to compare the lab results with your results to
• 52:05
  Speaker 1: see where there's a discrepancy that might be an interesting
• 52:09
  Speaker 1: Well do you think there will be discrepancies?
• 52:12
  Speaker 2: You know, uh, well probably, but but you know, again,
• 52:16
  Speaker 2: the only thing that's that really matters again is how
• 52:20
  Speaker 2: predictive it is of outcomes.
• 52:21
  Speaker 3: Right.
• 52:21
  Speaker 2: And so again, if you were going to compare your
• 52:23
  Speaker 2: your glucose en ra HbA one C, they wouldn't be
• 52:26
  Speaker 2: highly correlated because one is a point in time, the
• 52:28
  Speaker 2: other one's an average. Ours is that average? Right? And
• 52:32
  Speaker 2: so there might be some discrepancies. But again that's why
• 52:34
  Speaker 2: we we publish, That's why we have this data to
• 52:37
  Speaker 2: show that that our markers are effective and validated, and.
• 52:41
  Speaker 1: Just to everybody to know, all you have to do
• 52:43
  Speaker 1: is get a prick of your blood on your finger
• 52:46
  Speaker 1: and they put it on a you put it on
• 52:48
  Speaker 1: a card and you fill in the little circle of
• 52:50
  Speaker 1: the card. Do you have a picture of that anywhere?
• 52:53
  Speaker 2: Unfortunately I don't have one readily available, but I have it.
• 52:56
  Speaker 1: In my I have it in my photo gallery because
• 52:59
  Speaker 1: I took a pic when I was at the lab
• 53:02
  Speaker 1: and she, yeah, there it is, you have it right, Yeah.
• 53:06
  Speaker 2: This is just you know, a small fingerstick circle right there, which.
• 53:10
  Speaker 1: Is it's unbelievable. I mean, compare that to twenty vials
• 53:13
  Speaker 1: of blood. How you feel afterwards? You know, well, Ryan,
• 53:19
  Speaker 1: how did people reach you to get the test? That?
• 53:21
  Speaker 1: That's really important?
• 53:23
  Speaker 2: Yeah, so true Diagnostic dot com is the best place,
• 53:25
  Speaker 2: you know, you can order the test directly. You know,
• 53:28
  Speaker 2: we do oftentimes recommend taking it to your provider to
• 53:30
  Speaker 2: help analyze and interpret. And you need help with the
• 53:33
  Speaker 2: recommendation of provider, feel free to reach out to us
• 53:35
  Speaker 2: and we're happy to do it. You can also find
• 53:37
  Speaker 2: me on LinkedIn and you know, really the only place
• 53:40
  Speaker 2: that I'm active, but feel free to reach out if
• 53:42
  Speaker 2: anyone has any questions or needs to be connected to
• 53:45
  Speaker 2: a provider.
• 53:46
  Speaker 1: And not only that, but Ryan has very graciously done
• 53:49
  Speaker 1: a number of podcasts. I was watching you this morning
• 53:52
  Speaker 1: on Sam to Hatta and Joy you know doctor Joy Kong.
• 53:57
  Speaker 1: I think a cong is her name anyway, those are
• 53:59
  Speaker 1: the too that I just came up. But if you
• 54:02
  Speaker 1: google your name under our YouTube, you you're very generous
• 54:06
  Speaker 1: with your time and really helping people to understand more
• 54:10
  Speaker 1: about the not only the science, but the you know,
• 54:13
  Speaker 1: just the efficacy of these results that can save people
• 54:18
  Speaker 1: so much time.
• 54:19
  Speaker 2: So a huge believer in preventative help, and I think
• 54:23
  Speaker 2: this is really true preventative help.
• 54:25
  Speaker 1: Yeah. So, well, before we close, Ryan, what's next, you know,
• 54:29
  Speaker 1: other than what you've already talked about. I know all
• 54:32
  Speaker 1: these incredible advances that you're making, but what else do
• 54:35
  Speaker 1: you have in mind for two diagnostics?
• 54:37
  Speaker 2: Well, I'll tell you at the end of the day.
• 54:39
  Speaker 2: My vision is to have one diagnostic you do twice
• 54:42
  Speaker 2: per year that can report on your risk of every disease,
• 54:44
  Speaker 2: report on your risk of lifestyle things that might be
• 54:47
  Speaker 2: a problem. And I think ultimately we're going to get there.
• 54:50
  Speaker 2: One of the ways we're getting there is creating the
• 54:52
  Speaker 2: biggest combination of multiomic biological data, and ultimately we're going
• 54:57
  Speaker 2: to start to get a lot of FDA approved tests
• 54:59
  Speaker 2: across a lot of So I really do think that
• 55:01
  Speaker 2: with one drop of blood, you know, we can start
• 55:04
  Speaker 2: to do some really great, low cost, highly accessible healthcare.
• 55:08
  Speaker 2: That's the indivision how we go there. We'll start with
• 55:11
  Speaker 2: aging and then expand to other disease.
• 55:13
  Speaker 1: And then you were saying in the letter that I
• 55:16
  Speaker 1: got this morning, that could do it three do it
• 55:19
  Speaker 1: every three months. So you're saying now twice a year,
• 55:21
  Speaker 1: but that's a goal, but you're for now is it
• 55:24
  Speaker 1: still four times a year?
• 55:27
  Speaker 2: Yeah? You know, you can take it at really whatever
• 55:29
  Speaker 2: interval you'd like. We've even seen changes as little as
• 55:32
  Speaker 2: three weeks with things like our hyperbaric studies. You know,
• 55:35
  Speaker 2: I think that my goal is to get insurance reimbursed
• 55:37
  Speaker 2: twice a year by Medicaid, medicare as well as any insurance.
• 55:43
  Speaker 1: And is it now available for insurance not?
• 55:47
  Speaker 2: And we're working on that right now. Unfortunately, the FDA
• 55:49
  Speaker 2: doesn't have a recognized aging as a disease, but that's
• 55:53
  Speaker 2: really what we're going to change.
• 55:54
  Speaker 3: Yeah.
• 55:54
  Speaker 1: No, I had Eric Burdon from the Buck Institute, the CEO,
• 55:58
  Speaker 1: and you know, we got into that discussion about is
• 56:01
  Speaker 1: anything the disease and or you know, how do you
• 56:03
  Speaker 1: define aging? And so he said no, his contemporary say,
• 56:08
  Speaker 1: it's not a disease. I think he's coming more from
• 56:10
  Speaker 1: that allopathic model for that, even though the Buck Institute
• 56:14
  Speaker 1: is becoming much more of a functional medicine. But anyway,
• 56:18
  Speaker 1: he said, no, it is not a disease. So what
• 56:20
  Speaker 1: is it then? If it isn't a disease?
• 56:23
  Speaker 2: Yeah, this progressive deterioration. You know it it goes back
• 56:27
  Speaker 2: to the definition of a disease. But I think ultimately
• 56:30
  Speaker 2: it doesn't matter how we call it a disease or not.
• 56:32
  Speaker 2: If the if the FDA can prioritize the usefulness of
• 56:35
  Speaker 2: a diagnostic, that's all we care about it. And they
• 56:38
  Speaker 2: are in that grain I mentioned they're applying for. It's
• 56:40
  Speaker 2: called something a little bit different. It's not called aging,
• 56:42
  Speaker 2: it's called intrinsic capacity, but it's the same principle.
• 56:46
  Speaker 1: Well, hopefully with Robert F. Kennedy and the change of
• 56:49
  Speaker 1: the direction, that you're going to have a lot more
• 56:53
  Speaker 1: support for what you're doing, don't you think.
• 56:55
  Speaker 2: I hope, So, you know, fingers crossed the You know,
• 56:58
  Speaker 2: unfortunately a lot of our research laborators are starting to
• 57:01
  Speaker 2: lose funding in this environment, which is not something I
• 57:04
  Speaker 2: love to see. But I'm hoping the nih can still
• 57:07
  Speaker 2: get to keep their funding, and it's so important for
• 57:09
  Speaker 2: everything that we do.
• 57:10
  Speaker 1: No. I know that Eric was saying the exact same thing,
• 57:13
  Speaker 1: that about fifty percent of their funding is NURH and
• 57:16
  Speaker 1: that's being curtailed. So yeah, we've got to find a
• 57:19
  Speaker 1: balance because I mean, obviously RFK recognizes that being in
• 57:24
  Speaker 1: the eightieth percentile of the you know, the nations in
• 57:31
  Speaker 1: the world, and particularly the progressive nations like the United States,
• 57:35
  Speaker 1: it should be we should be number one for the
• 57:37
  Speaker 1: amount that we spend in healthcare. And look at our
• 57:40
  Speaker 1: track record, it's it's really quite deplorable.
• 57:43
  Speaker 2: It is we need improvements and again, but if this
• 57:46
  Speaker 2: systematic framework is a way to do it, so I'm
• 57:49
  Speaker 2: hoping that we'll see some change. But ultimately, if there's
• 57:51
  Speaker 2: one takeaway for anyone listening, it's it's treat aging as
• 57:55
  Speaker 2: something you can change and modify.
• 57:56
  Speaker 1: The epigenetics side, Ryan, I have to try before we close.
• 58:01
  Speaker 1: You are one of my big heroes. And you know,
• 58:04
  Speaker 1: as I got into this world, I mean I've been
• 58:07
  Speaker 1: passionate about functional medicine for many, many years, but when
• 58:11
  Speaker 1: I really put my two feet in with six years
• 58:16
  Speaker 1: ago with the podcast and now I write an article
• 58:19
  Speaker 1: for Top Doctor magazine monthly, and so this is you know,
• 58:26
  Speaker 1: why are you my hero? Well, because I see someone
• 58:28
  Speaker 1: really young who you know, just took a risk and truly,
• 58:34
  Speaker 1: I mean this was a risk. You left medical school,
• 58:36
  Speaker 1: you gave up the traditional financial model, and you took
• 58:41
  Speaker 1: this risk and look where we are today for all
• 58:44
  Speaker 1: of your work, and yet you're so young, so we
• 58:47
  Speaker 1: have so much more to anticipate with all your incredible
• 58:51
  Speaker 1: energy and your wonderful spirit and positive attitude. So thank
• 58:56
  Speaker 1: you so much for doing all you can for all
• 58:59
  Speaker 1: of us.
• 59:00
  Speaker 2: Likewise, Michelle, you know, I get my head buried in
• 59:03
  Speaker 2: these papers and books, and sometimes it's hard to explain
• 59:06
  Speaker 2: all the work we're doing in the vision that we have,
• 59:07
  Speaker 2: and so I thank you for having me on and
• 59:09
  Speaker 2: letting me tell the story.
• 59:10
  Speaker 1: Well, you're you're you know you've done this for many
• 59:13
  Speaker 1: other podcasts, but I take great honor that you have
• 59:17
  Speaker 1: been on ours twice. So all right, Ryan, Well you
• 59:19
  Speaker 1: have a wonderful fourth of July, and thank you again,
• 59:23
  Speaker 1: and I'll see you probably in December at a four
• 59:25
  Speaker 1: a M.
• 59:26
  Speaker 2: Let's do it. Thank you so much, Michelle,